Neuroblastoma Explained

Neuroblastoma
Field:Neuro-oncology
Symptoms:Bone pain, lumps
Onset:Under 5 years old
Causes:Genetic mutation
Diagnosis:Tissue biopsy
Treatment:Observation, surgery, radiation, chemotherapy, stem cell transplantation
Prognosis:US five-year survival ~95% (< 1 year old), 68% (1–14 years old)
Frequency:1 in 7,000 children
Deaths:15% of deaths due to cancer in children

Neuroblastoma (NB) is a type of cancer that forms in certain types of nerve tissue. It most frequently starts from one of the adrenal glands but can also develop in the head, neck, chest, abdomen, or spine. Symptoms may include bone pain, a lump in the abdomen, neck, or chest, or a painless bluish lump under the skin.[1]

Typically, neuroblastoma occurs due to a genetic mutation occurring in the first trimester of pregnancy.[2] Rarely, it may be due to a mutation inherited.[1] Environmental factors have not been found to be involved. Diagnosis is based on a tissue biopsy.[1] Occasionally, it may be found in a baby by ultrasound during pregnancy.[1] At diagnosis, the cancer has usually already spread.[1] The cancer is divided into low-, intermediate-, and high-risk groups based on a child's age, cancer stage, and what the cancer looks like.[1]

Treatment and outcomes depends on the risk group a person is in.[1] Treatments may include observation, surgery, radiation, chemotherapy, or stem cell transplantation.[1] Low-risk disease in babies typically has a good outcome with surgery or simply observation. In high-risk disease, chances of long-term survival, however, are less than 40%, despite aggressive treatment.[3]

Neuroblastoma is the most common cancer in babies and the third-most common cancer in children after leukemia and brain cancer.[3] About one in every 7,000 children is affected at some time.[4] About 90% of cases occur in children less than 5 years old, and it is rare in adults.[4] Of cancer deaths in children, about 15% are due to neuroblastoma.[5] The disease was first described in the 1800s.[6]

Signs and symptoms

The first symptoms of neuroblastoma are often vague, making diagnosis difficult. Fatigue, loss of appetite, fever, and joint pain are common. Symptoms depend on primary tumor locations and metastases if present:[7]

Neuroblastoma often spreads to other parts of the body before any symptoms are apparent, and 50 to 60% of all neuroblastoma cases present with metastases.[8]

The most common location for neuroblastoma to originate (i.e., the primary tumor) is in the adrenal glands. This occurs in 40% of localized tumors and in 60% of cases of widespread disease. Neuroblastoma can also develop anywhere along the sympathetic nervous system chain from the neck to the pelvis. Frequencies in different locations include: neck (1%), chest (19%), abdomen (30% nonadrenal), or pelvis (1%). In rare cases, no primary tumor can be discerned.[9]

Rare but characteristic presentations include transverse myelopathy (tumor spinal cord compression, 5% of cases), treatment-resistant diarrhea (tumor vasoactive intestinal peptide secretion, 4% of cases), Horner's syndrome (cervical tumor, 2.4% of cases), opsoclonus myoclonus syndrome[10] and ataxia (suspected paraneoplastic cause, 1.3% of cases), and hypertension (catecholamine secretion or kidney artery compression, 1.3% of cases).[11]

Cause

The cause of neuroblastoma is not well understood. The great majority of cases are sporadic and nonfamilial. About 1–2% of cases run in families and have been linked to specific gene mutations. Familial neuroblastoma in some cases is caused by rare germline mutations in the anaplastic lymphoma kinase (ALK) gene.[12] Germline mutations in the PHOX2B or KIF1B gene have been implicated in familial neuroblastoma, as well. Neuroblastoma is also a feature of neurofibromatosis type 1 and the Beckwith-Wiedemann syndrome.

MYCN oncogene amplification within the tumor is a common finding in neuroblastoma. The degree of amplification shows a bimodal distribution: either 3- to 10-fold, or 100- to 300-fold. The presence of this mutation is highly correlated to advanced stages of disease.[13]

Duplicated segments of the LMO1 gene within neuroblastoma tumor cells have been shown to increase the risk of developing an aggressive form of the cancer.[14]

Other genes might have a prognostic role in neuroblastoma. A bioinformatics study published in 2023 suggested that the AHCY, DPYSL3, and NME1 genes might have a prognostic role in this disease.[15]

Neuroblastoma has been linked to copy-number variation within the NBPF10 gene, which results in the 1q21.1 deletion syndrome or 1q21.1 duplication syndrome.[16]

One study strongly indicates that miRNAs that are excessively expressed in 1p-deleted neuroblastoma cells, as opposed to other genetic subgroups of neuroblastoma, could potentially disrupt the regulation of genes associated with neuronal differentiation, thereby contribute to the pathogenesis of neuroblastoma. Furthermore, it was noted that miR-495 primarily targeted the majority of mRNAs that are involved in neuronal differentiation.[17]

Several risk factors have been proposed and are the subject of ongoing research. Due to characteristic early onset, many studies have focused on parental factors around conception and during gestation. Factors investigated have included occupation (i.e. exposure to chemicals in specific industries), smoking, alcohol consumption, use of medicinal drugs during pregnancy, and birth factors; however, results have been inconclusive.[18]

Other studies have examined possible links with atopy and exposure to infection early in life,[19] use of hormones and fertility drugs,[20] and maternal use of hair dye.[21] [22]

Diagnosis

The diagnosis is usually confirmed by a surgical pathologist, taking into account the clinical presentation, microscopic findings, and other laboratory tests. It may arise from any neural crest element of the sympathetic nervous system (SNS).

Esthesioneuroblastoma, also known as olfactory neuroblastoma, is believed to arise from the olfactory epithelium and its classification remains controversial. However, since it is not a sympathetic nervous system malignancy, esthesioneuroblastoma is a distinct clinical entity and is not to be confused with neuroblastoma.[23]

Biochemistry

In about 90% of cases of neuroblastoma, elevated levels of catecholamines or their metabolites are found in the urine or blood. Catecholamines and their metabolites include dopamine, homovanillic acid (HVA), and/or vanillylmandelic acid (VMA).[24]

Imaging

Another way to detect neuroblastoma is the meta-iodobenzylguanidine scan, which is taken up by 90 to 95% of all neuroblastomas, often termed "mIBG-avid". The mechanism is that mIBG is taken up by sympathetic neurons, and is a functioning analog of the neurotransmitter norepinephrine. When it is radio-iodinated with I-131 or I-123 (radioactive iodine isotopes), it is a very good radiopharmaceutical for diagnosis and monitoring of response to treatment for this disease. With a half-life of 13 hours, I-123 is the preferred isotope for imaging sensitivity and quality. I-131 has a half-life of 8 days and at higher doses is an effective therapy as targeted radiation against relapsed and refractory neuroblastoma.[25] As mIBG is not always taken up by neuroblastomas, researchers have explored in children with neuroblastoma whether another type of nuclear imaging, fluoro-deoxy-glucose – positron emission tomography, often termed "F-FDG-PET", might be useful.[26] Evidence suggests that this might be advisable to use in children with neuroblastoma for which mIBG does not work, but more research is needed in this area.[26]

Histology

On microscopy, the tumor cells are typically described as small, round and blue, and rosette patterns (Homer Wright pseudorosettes) may be seen. Homer Wright pseudorosettes are tumor cells around the neuropil, not to be confused with a true rosettes, which are tumor cells around an empty lumen.[27] They are also distinct from the pseudorosettes of an ependymoma which consist of tumor cells with glial fibrillary acidic protein (GFAP)–positive processes tapering off toward a blood vessel (thus a combination of the two). A variety of immunohistochemical stains are used by pathologists to distinguish neuroblastomas from histological mimics, such as rhabdomyosarcoma, Ewing's sarcoma, lymphoma and Wilms' tumor.[28]

Neuroblastoma is one of the peripheral neuroblastic tumors (pNTs) that have similar origins and show a wide pattern of differentiation ranging from benign ganglioneuroma to stroma-rich ganglioneuroblastoma with neuroblastic cells intermixed or in nodules, to highly malignant neuroblastoma. This distinction in the pre-treatment tumor pathology is an important prognostic factor, along with age and mitosis-karyorrhexis index (MKI). This pathology classification system (the Shimada system) describes "favorable" and "unfavorable" tumors by the International Neuroblastoma Pathology Committee (INPC) which was established in 1999 and revised in 2003.[29]

Staging

The "International Neuroblastoma Staging System" (INSS) established in 1986 and revised in 1988 stratifies neuroblastoma according to its anatomical presence at diagnosis:[30] [31] [32]

Although international agreement on staging (INSS) has been used, the need for an international consensus on risk assignment has also been recognized in order to compare similar cohorts in results of studies. Beginning in 2005, representatives of the major pediatric oncology cooperative groups have met to review data for 8,800 people with neuroblastoma treated in Europe, Japan, USA, Canada, and Australia between 1990 and 2002. This task force has proposed the International Neuroblastoma Risk Group (INRG) classification system. Retrospective studies revealed the high survival rate of 12–18 month-old age group, previously categorized as high-risk, and prompted the decision to reclassify 12–18 month-old children without N-myc (also commonly referred to as MYCN) amplification to intermediate risk category.[33]

The new INRG risk assignment will classify neuroblastoma at diagnosis based on a new International Neuroblastoma Risk Group Staging System (INRGSS):

The new risk stratification will be based on the new INRGSS staging system, age (dichotomized at 18 months), tumor grade, N-myc amplification, unbalanced 11q aberration, and ploidy into four pre-treatment risk groups: very low, low, intermediate, and high risk.[3] [34]

Screening

Urine catecholamine level can be elevated in pre-clinical neuroblastoma. Screening asymptomatic infants at three weeks, six months, and one year has been performed in Japan, Canada, Austria and Germany since the 1980s.[35] [36] Japan began screening six-month-olds for neuroblastoma via analysis of the levels of homovanillic acid and vanilmandelic acid in 1984. Screening was halted in 2004 after studies in Canada and Germany showed no reduction in deaths due to neuroblastoma, but rather caused an increase in diagnoses that would have disappeared without treatment, subjecting those infants to unnecessary surgery and chemotherapy.[37] [38] [39]

Treatment

When the lesion is localized, it is generally curable. However, long-term survival for children with advanced disease older than 18 months of age is poor despite aggressive multimodal therapy (intensive chemotherapy, surgery, radiation therapy, stem cell transplant, differentiation agent isotretinoin also called 13-cis-retinoic acid, and frequently immunotherapy[40] with anti-GD2 monoclonal antibody therapy – dinutuximab).

Biologic and genetic characteristics have been identified, which, when added to classic clinical staging, has allowed assignment to risk groups for planning treatment intensity.[41] These criteria include the age of the person, extent of disease spread, microscopic appearance, and genetic features including DNA ploidy and N-myc oncogene amplification (N-myc regulates microRNAs[42]), into low, intermediate, and high risk disease. A recent biology study (COG ANBL00B1) analyzed 2687 people with neuroblastoma and the spectrum of risk assignment was determined: 37% of neuroblastoma cases are low risk, 18% are intermediate risk, and 45% are high risk.[43] (There is some evidence that the high- and low-risk types are caused by different mechanisms, and are not merely two different degrees of expression of the same mechanism.)[44]

The therapies for these different risk categories are very different.

People with low and intermediate risk disease have an excellent prognosis with cure rates above 90% for low risk and 70–90% for intermediate risk. In contrast, therapy for high-risk neuroblastoma the past two decades resulted in cures only about 30% of the time.[51] The addition of antibody therapy has raised survival rates for high-risk disease significantly. In March 2009, an early analysis of a Children's Oncology Group (COG) study with 226 people that are high-risk showed that two years after stem cell transplant 66% of the group randomized to receive ch14.18 antibody with GM-CSF and IL-2 were alive and disease-free compared to only 46% in the group that did not receive the antibody. The randomization was stopped so all people enrolling on the trial would receive the antibody therapy.[52]

Chemotherapy agents used in combination have been found to be effective against neuroblastoma. Agents commonly used in induction and for stem cell transplant conditioning are platinum compounds (cisplatin, carboplatin), alkylating agents (cyclophosphamide, ifosfamide, melphalan), topoisomerase II inhibitor (etoposide), anthracycline antibiotics (doxorubicin) and vinca alkaloids (vincristine). Some newer regimens include topoisomerase I inhibitors (topotecan and irinotecan) in induction which have been found to be effective against recurrent disease. Although further research is needed, interventions currently under pre-clinical investigation include epigenetic therapies, such as inhibition of SWI/SNF,[53] which may complement existing retinoid therapies.

In November 2020, naxitamab was approved for medical use in the United States in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to treat people one year of age and older with high-risk neuroblastoma in bone or bone marrow whose tumor did not respond to or has come back after previous treatments and has shown a partial response, minor response, or stable disease to prior therapy.[54] [55]

Prognosis

By data from England, the overall 5-year survival rate of neuroblastoma is 67%.[56] Between 20% and 50% of high-risk cases do not respond adequately to induction high-dose chemotherapy and are progressive or refractory.[57] [58] Relapse after completion of frontline therapy is also common. Further treatment is available in phase I and phase II clinical trials that test new agents and combinations of agents against neuroblastoma, but the outcome remains very poor for relapsed high-risk disease.[59]

Most long-term survivors alive today had low or intermediate risk disease and milder courses of treatment compared to high-risk disease. The majority of survivors have long-term effects from the treatment. Survivors of intermediate and high-risk treatment often experience hearing loss, growth reduction, thyroid function disorders, learning difficulties, and greater risk of secondary cancers affect survivors of high-risk disease.[60] [61] An estimated two of three survivors of childhood cancer will ultimately develop at least one chronic and sometimes life-threatening health problem within 20 to 30 years after the cancer diagnosis.[62] [63] [64]

Cytogenetic profiles

Based on a series of 493 neuroblastoma samples, it has been reported that overall genomic pattern, as tested by array-based karyotyping, is a predictor of outcome in neuroblastoma:[65]

Earlier publications categorized neuroblastomas into three major subtypes based on cytogenetic profiles:[66] [67]

Virtual karyotyping can be performed on fresh or paraffin-embedded tumors to assess copy number at these loci. SNP array virtual karyotyping is preferred for tumor samples, including neuroblastomas, because they can detect copy neutral loss of heterozygosity (acquired uniparental disomy). Copy neutral LOH can be biologically equivalent to a deletion and has been detected at key loci in neuroblastoma.[68] ArrayCGH, FISH, or conventional cytogenetics cannot detect copy neutral LOH.

Epidemiology

Neuroblastoma comprises 6–10% of all childhood cancers, and 15% of cancer deaths in children. The annual mortality rate is 10 per million children in the 0- to 4-year-old age group, and 4 per million in the 4- to 9-year old age group.[69]

The highest number of cases is in the first year of life, and some cases are congenital. The age range is broad, including older children and adults,[70] but only 10% of cases occur in people older than 5 years of age.[71] A large European study reported less than 2% of over 4000 neuroblastoma cases were over 18 years old.[72]

History

In 1864 German physician Rudolf Virchow was the first to describe an abdominal tumor in a child as a "glioma". The characteristics of tumors from the sympathetic nervous system and the adrenal medulla were then noted in 1891 by German pathologist Felix Marchand.[73] [74] In 1901 the distinctive presentation of stage 4S in infants (liver but no bone metastases) was described by William Pepper. In 1910 James Homer Wright understood the tumor to originate from primitive neural cells, and named it neuroblastoma. He also noted the circular clumps of cells in bone marrow samples which are now termed "Homer Wright rosettes". Of note, "Homer-Wright" with a hyphen is grammatically incorrect, as the eponym refers to just Dr. Wright.[75]

Scientific research

Preclinical models

Neuroblastoma patient derived tumor xenografts (PDXs) have been created by orthotopic implantation of tumor samples into immunodeficient mice.[76] PDX models have several advantages over conventional cancer cell lines (CCL)s.[77] Neuroblastoma PDXs retain the genetic hallmarks of their corresponding tumors and PDXs display infiltrative growth and metastasis to distant organs. PDX models are more predictive of clinical outcome as compared to conventional cancer cell line xenografts.[78] Neuroblastoma PDXs might thus serve as clinically relevant models to identify effective compounds against neuroblastoma.

Treatments

Recent focus has been to reduce therapy for low and intermediate risk neuroblastoma while maintaining survival rates at 90%.[79] A study of 467 people that are at intermediate risk enrolled in A3961 from 1997 to 2005 confirmed the hypothesis that therapy could be successfully reduced for this risk group. Those with favorable characteristics (tumor grade and response) received four cycles of chemotherapy, and those with unfavorable characteristics received eight cycles, with three-year event free survival and overall survival stable at 90% for the entire cohort. Future plans are to intensify treatment for those people with aberration of 1p36 or 11q23 chromosomes as well as for those who lack early response to treatment.[80] [81]

By contrast, focus the past 20 years or more has been to intensify treatment for high-risk neuroblastoma. Chemotherapy induction variations, timing of surgery, stem cell transplant regimens, various delivery schemes for radiation, and use of monoclonal antibodies and retinoids to treat minimal residual disease continue to be examined. Recent phase III clinical trials with randomization have been carried out to answer these questions to improve survival of high-risk disease:

Refractory and relapsed neuroblastoma

Chemotherapy with topotecan and cyclophosphamide is frequently used in refractory setting and after relapse.[82]

A haploidentical stem cell transplant, that is, donor cells derived from parents, is being studied in those with refractory or relapsing neuroblastoma as stem cells from the person themselves is not useful.[83]

It has been shown that neuroblastoma display a high expression of somatostatin receptors [84] [85] [86] and this enables potential therapy using 177Lu-DOTA-TATE, a type of radionuclide therapy that specifically targets the somatostatin receptors. Several early phase clinical trials using 177Lu-DOTA-TATE for treatment of high-risk refractory/relapsed neuroblastoma have been conducted with promising results.[87] [88] [89]

Electronic health records' data

Several international initiatives have been recently launched for the sharing of data of electronic health records of patients with neuroblastoma: these data in fact can be analyzed with machine learning and statistics models to infer new knowledge about this disease.To this end, the International Neuroblastoma Risk Group (INRG) recently released the INRG Data Commons,[90] while University of Chicago launched the Pediatric Cancer Data Commons.[91] These two repositories contain data of electronic health records of thousands of patients that are available for scientific research, with prior authorization.In 2022, researchers released a new data repository of electronic health records called Neuroblastoma Electronic Health Records Open Data Repository where data can be downloaded freely without any restriction.

Organisations

The Advances in Neuroblastoma Research Association (ANRA) is the peak body for researchers in neuroblastoma biology, diagnosis, prognosis, and therapy, and conducts meetings every two years to exchange information among them.[92]

External links

Notes and References

  1. Web site: Neuroblastoma Treatment. National Cancer Institute. 9 November 2016. 20 January 2016. live. https://web.archive.org/web/20161110050003/https://www.cancer.gov/types/neuroblastoma/patient/neuroblastoma-treatment-pdq#section/all. 10 November 2016.
  2. Körber . Verena . Stainczyk . Sabine A. . Kurilov . Roma . Henrich . Kai-Oliver . Hero . Barbara . Brors . Benedikt . Westermann . Frank . Höfer . Thomas . April 2023 . Neuroblastoma arises in early fetal development and its evolutionary duration predicts outcome . Nature Genetics . 55 . 4 . 619–630 . 10.1038/s41588-023-01332-y . 1546-1718 . 36973454. free . 10101850 .
  3. Maris JM, Hogarty MD, Bagatell R, Cohn SL . Neuroblastoma . Lancet . 369 . 9579 . 2106–2120 . June 2007 . 17586306 . 10.1016/S0140-6736(07)60983-0 . 208790138 .
  4. Web site: Neuroblastoma Treatment. National Cancer Institute. 10 November 2016. 25 August 2016. live. https://web.archive.org/web/20161110110721/https://www.cancer.gov/types/neuroblastoma/hp/neuroblastoma-treatment-pdq#section/all. 10 November 2016.
  5. Book: World Cancer Report 2014. 2014. World Health Organization. 978-92-832-0429-9. Chapter 5.16. https://web.archive.org/web/20160919073553/http://publications.iarc.fr/Non-Series-Publications/World-Cancer-Reports/World-Cancer-Report-2014. 2016-09-19. 2016-11-10.
  6. Book: Olson JS . The History of Cancer: An Annotated Bibliography. 1989. ABC-CLIO. 978-0-313-25889-3. 177. en. live. https://web.archive.org/web/20170910182643/https://books.google.com/books?id=oAX8jOJ9uO0C&pg=PA177. 2017-09-10.
  7. Web site: Neuroblastoma in children . January 1, 2013 . Wheeler K . Macmillan . live . https://web.archive.org/web/20151005221946/http://www.macmillan.org.uk/Cancerinformation/Cancertypes/Childrenscancers/Typesofchildrenscancers/Neuroblastoma.aspx . October 5, 2015 .
  8. Web site: Neuroblastoma: Pediatric Cancers: Merck Manual Professional . 2008-01-01 . live . https://web.archive.org/web/20071218193442/http://www.merck.com/mmpe/sec19/ch285/ch285b.html . 2007-12-18 .
  9. Friedman GK, Castleberry RP . Changing trends of research and treatment in infant neuroblastoma . Pediatric Blood & Cancer . 49 . 7 Suppl . 1060–1065 . December 2007 . 17943963 . 10.1002/pbc.21354 . 37657305 .
  10. Rothenberg AB, Berdon WE, D'Angio GJ, Yamashiro DJ, Cowles RA . The association between neuroblastoma and opsoclonus-myoclonus syndrome: a historical review . Pediatric Radiology . 39 . 7 . 723–726 . July 2009 . 19430769 . 10.1007/s00247-009-1282-x . 24523263 .
  11. Book: Cheung NK . Neuroblastoma . . 66–7 . 2005 . 978-3-540-40841-3 .
  12. Mossé YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, Laquaglia MJ, Sennett R, Lynch JE, Perri P, Laureys G, Speleman F, Kim C, Hou C, Hakonarson H, Torkamani A, Schork NJ, Brodeur GM, Tonini GP, Rappaport E, Devoto M, Maris JM . 6 . Identification of ALK as a major familial neuroblastoma predisposition gene . Nature . 455 . 7215 . 930–935 . October 2008 . 18724359 . 2672043 . 10.1038/nature07261 . 2008Natur.455..930M .
  13. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM . Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage . Science . 224 . 4653 . 1121–1124 . June 1984 . 6719137 . 10.1126/science.6719137 . 1984Sci...224.1121B .
  14. Wang K, Diskin SJ, Zhang H, Attiyeh EF, Winter C, Hou C, Schnepp RW, Diamond M, Bosse K, Mayes PA, Glessner J, Kim C, Frackelton E, Garris M, Wang Q, Glaberson W, Chiavacci R, Nguyen L, Jagannathan J, Saeki N, Sasaki H, Grant SF, Iolascon A, Mosse YP, Cole KA, Li H, Devoto M, McGrady PW, London WB, Capasso M, Rahman N, Hakonarson H, Maris JM . 6 . Integrative genomics identifies LMO1 as a neuroblastoma oncogene . Nature . 469 . 7329 . 216–220 . January 2011 . 21124317 . 3320515 . 10.1038/nature09609 . 2011Natur.469..216W .
  15. Chicco . Davide . Sanavia . Tiziana . Jurman . Giuseppe . Signature literature review reveals AHCY, DPYSL3, and NME1 as the most recurrent prognostic genes for neuroblastoma . BioData Mining . 4 March 2023 . 16 . 1 . 7 . 1756-0381 . 10.1186/s13040-023-00325-1 . 36870971 . 9985261 . free .
  16. Diskin SJ, Hou C, Glessner JT, Attiyeh EF, Laudenslager M, Bosse K, Cole K, Mossé YP, Wood A, Lynch JE, Pecor K, Diamond M, Winter C, Wang K, Kim C, Geiger EA, McGrady PW, Blakemore AI, London WB, Shaikh TH, Bradfield J, Grant SF, Li H, Devoto M, Rappaport ER, Hakonarson H, Maris JM . 6 . Copy number variation at 1q21.1 associated with neuroblastoma . Nature . 459 . 7249 . 987–991 . June 2009 . 19536264 . 2755253 . 10.1038/nature08035 . 2009Natur.459..987D .
  17. Altungoz . Oguz . Timer . Bagci . 17 February 2023 . Chromosome 1p status in neuroblastoma correlates with higher expression levels of miRNAs targeting neuronal differentiation pathway . . 59 . 2 . 100–108 . 10.1007/s11626-023-00750-w . 36800078 . Springer.
  18. Book: Olshan AF, Bunin GR . 2000 . Epidemiology of Neuroblastoma . Brodeur GM, Sawada T, Tsuchida Y, Voûte PP . Neuroblastoma . Elsevier . Amsterdam . 33–9 . 978-0-444-50222-3.
  19. Menegaux F, Olshan AF, Neglia JP, Pollock BH, Bondy ML . Day care, childhood infections, and risk of neuroblastoma . American Journal of Epidemiology . 159 . 9 . 843–851 . May 2004 . 15105177 . 2080646 . 10.1093/aje/kwh111 .
  20. Olshan AF, Smith J, Cook MN, Grufferman S, Pollock BH, Stram DO, Seeger RC, Look AT, Cohn SL, Castleberry RP, Bondy ML . 6 . Hormone and fertility drug use and the risk of neuroblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group . American Journal of Epidemiology . 150 . 9 . 930–938 . November 1999 . 10547138 . 10.1093/oxfordjournals.aje.a010101 . free .
  21. McCall EE, Olshan AF, Daniels JL . Maternal hair dye use and risk of neuroblastoma in offspring . Cancer Causes & Control . 16 . 6 . 743–748 . August 2005 . 16049813 . 10.1007/s10552-005-1229-y . 24323871 .
  22. Heck JE, Ritz B, Hung RJ, Hashibe M, Boffetta P . The epidemiology of neuroblastoma: a review . Paediatric and Perinatal Epidemiology . 23 . 2 . 125–143 . March 2009 . 19159399 . 10.1111/j.1365-3016.2008.00983.x .
  23. Book: Cheung NK . Neuroblastoma . . 73 . 2005 . 978-3-540-40841-3 .
  24. Strenger V, Kerbl R, Dornbusch HJ, Ladenstein R, Ambros PF, Ambros IM, Urban C . Diagnostic and prognostic impact of urinary catecholamines in neuroblastoma patients . Pediatric Blood & Cancer . 48 . 5 . 504–509 . May 2007 . 16732582 . 10.1002/pbc.20888 . 34838939 .
  25. Pashankar FD, O'Dorisio MS, Menda Y . MIBG and somatostatin receptor analogs in children: current concepts on diagnostic and therapeutic use . Journal of Nuclear Medicine . 46 . Suppl 1 . 55S–61S . January 2005 . 15653652 .
  26. Bleeker G, Tytgat GA, Adam JA, Caron HN, Kremer LC, Hooft L, van Dalen EC . 123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma . The Cochrane Database of Systematic Reviews . 9 . CD009263 . September 2015 . 2015 . 26417712 . 4621955 . 10.1002/14651858.cd009263.pub2 .
  27. Book: Robbins and Cotran pathologic basis of disease . 2015 . Elsevier . 978-1-4557-2613-4 . 9.
  28. Carter RL, al-Sams SZ, Corbett RP, Clinton S . A comparative study of immunohistochemical staining for neuron-specific enolase, protein gene product 9.5 and S-100 protein in neuroblastoma, Ewing's sarcoma and other round cell tumours in children . Histopathology . 16 . 5 . 461–467 . May 1990 . 2163356 . 10.1111/j.1365-2559.1990.tb01545.x . 6461880 .
  29. Peuchmaur M, d'Amore ES, Joshi VV, Hata J, Roald B, Dehner LP, Gerbing RB, Stram DO, Lukens JN, Matthay KK, Shimada H . 6 . Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular . Cancer . 98 . 10 . 2274–2281 . November 2003 . 14601099 . 10.1002/cncr.11773 . 27081822 . free .
  30. Web site: Neuroblastoma Treatment—National Cancer Institute . 2008-07-30 . live . https://web.archive.org/web/20081002182158/http://www.cancer.gov/cancertopics/pdq/treatment/neuroblastoma/HealthProfessional/page3#Section_185 . 2008-10-02 . 1980-01-01 .
  31. Brodeur GM, Seeger RC, Barrett A, Berthold F, Castleberry RP, D'Angio G, De Bernardi B, Evans AE, Favrot M, Freeman AI . 6 . International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma . Journal of Clinical Oncology . 6 . 12 . 1874–1881 . December 1988 . 3199170 . 10.1200/JCO.1988.6.12.1874 .
  32. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F . 6 . Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment . Journal of Clinical Oncology . 11 . 8 . 1466–1477 . August 1993 . 8336186 . 10.1200/JCO.1993.11.8.1466 .
  33. Schmidt ML, Lal A, Seeger RC, Maris JM, Shimada H, O'Leary M, Gerbing RB, Matthay KK . 6 . Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study . Journal of Clinical Oncology . 23 . 27 . 6474–6480 . September 2005 . 16116154 . 10.1200/JCO.2005.05.183 . free .
  34. Cohn SL, London WB, Monclair T, Matthay KK, Ambros PF, Pearson AD . 2007 . Update on the development of the international neuroblastoma risk group (INRG) classification schema . Journal of Clinical Oncology . 25 . 18 Suppl . 9503 . 10.1200/jco.2007.25.18_suppl.9503 . https://web.archive.org/web/20160110164845/http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/9503 . 2016-01-10 .
  35. Woods WG, Gao RN, Shuster JJ, Robison LL, Bernstein M, Weitzman S, Bunin G, Levy I, Brossard J, Dougherty G, Tuchman M, Lemieux B . 6 . Screening of infants and mortality due to neuroblastoma . The New England Journal of Medicine . 346 . 14 . 1041–1046 . April 2002 . 11932470 . 10.1056/NEJMoa012387 . free .
  36. Schilling FH, Spix C, Berthold F, Erttmann R, Sander J, Treuner J, Michaelis J . Children may not benefit from neuroblastoma screening at 1 year of age. Updated results of the population based controlled trial in Germany . Cancer Letters . 197 . 1–2 . 19–28 . July 2003 . 12880955 . 10.1016/S0304-3835(03)00077-6 .
  37. Tsubono Y, Hisamichi S . A halt to neuroblastoma screening in Japan . The New England Journal of Medicine . 350 . 19 . 2010–2011 . May 2004 . 15128908 . 10.1056/NEJM200405063501922 . free .
  38. Web site: Neuroblastoma Screening . National Cancer Institute . 2008-07-30 . live . https://web.archive.org/web/20081001234010/http://www.cancer.gov/cancertopics/pdq/screening/neuroblastoma/HealthProfessional/page3 . 2008-10-01 . 1980-01-01 .
  39. Darshak Sanghavi, "Screen Alert: How an Ounce of RX Prevention can Cause a Pound of Hurt", Slate magazine, November 28, 2006
  40. Johnson E, Dean SM, Sondel PM . Antibody-based immunotherapy in high-risk neuroblastoma . Expert Reviews in Molecular Medicine . 9 . 34 . 1–21 . December 2007 . 18081947 . 10.1017/S1462399407000518 . 32358612 .
  41. Brodeur GM . Neuroblastoma: biological insights into a clinical enigma . Nature Reviews. Cancer . 3 . 3 . 203–216 . March 2003 . 12612655 . 10.1038/nrc1014 . 6447457 .
  42. Schulte JH, Horn S, Otto T, Samans B, Heukamp LC, Eilers UC, Krause M, Astrahantseff K, Klein-Hitpass L, Buettner R, Schramm A, Christiansen H, Eilers M, Eggert A, Berwanger B . 6 . MYCN regulates oncogenic MicroRNAs in neuroblastoma . International Journal of Cancer . 122 . 3 . 699–704 . February 2008 . 17943719 . 10.1002/ijc.23153 . free .
  43. Web site: Translating Neuroblastoma Genomics to the Clinic—J. Maris presentation ASCO 2007 . https://web.archive.org/web/20090102150923/http://media.asco.org/player/default.aspx?LectureID=317&conferenceFolder=vm2007&SessionFolder=01028&slideonly=yes&TrackID=N929&LectureTitle=Translating%20Neuroblastoma%20Genomics%20to%20the%20Clinic&Key=vm_47_10_222_317&SpeakerName=%3B%20Chair%3A%20John%20M.%20Maris%2C%20MD&mediaURL=%2Fmedia&ServerName=media.asco.org&max=28&ext=jpg&useASX=false&playtype=&playtype=&playtype=%2C . 2009-01-02 . 2008-01-13 .
  44. Gisselsson D, Lundberg G, Ora I, Höglund M . Distinct evolutionary mechanisms for genomic imbalances in high-risk and low-risk neuroblastomas . Journal of Carcinogenesis . 6 . 15 . September 2007 . 17897457 . 2042979 . 10.1186/1477-3163-6-15 . free .
  45. Web site: Neuroblastoma Treatment . National Cancer Institute . 2008-02-02 . live . https://web.archive.org/web/20080503102850/http://www.cancer.gov/cancertopics/pdq/treatment/neuroblastoma/Patient/page5 . 2008-05-03 . 1980-01-01 .
  46. Haase GM, Perez C, Atkinson JB . Current aspects of biology, risk assessment, and treatment of neuroblastoma . Seminars in Surgical Oncology . 16 . 2 . 91–104 . March 1999 . 9988866 . 10.1002/(SICI)1098-2388(199903)16:2<91::AID-SSU3>3.0.CO;2-1 .
  47. Fish JD, Grupp SA . Stem cell transplantation for neuroblastoma . Bone Marrow Transplantation . 41 . 2 . 159–165 . January 2008 . 18037943 . 2892221 . 10.1038/sj.bmt.1705929 .
  48. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP . 6 . Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group . The New England Journal of Medicine . 341 . 16 . 1165–1173 . October 1999 . 10519894 . 10.1056/NEJM199910143411601 . free .
  49. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM . 6 . Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma . The New England Journal of Medicine . 363 . 14 . 1324–1334 . September 2010 . 20879881 . 3086629 . 10.1056/NEJMoa0911123 .
  50. Yalçin B, Kremer LC, van Dalen EC . High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma . The Cochrane Database of Systematic Reviews . 2015 . 10 . CD006301 . October 2015 . 26436598 . 8783746 . 10.1002/14651858.cd006301.pub4 .
  51. Web site: Neuroblastoma Treatment . National Cancer Institute . 2008-07-30 . live . https://web.archive.org/web/20081002182158/http://www.cancer.gov/cancertopics/pdq/treatment/neuroblastoma/HealthProfessional/page3#Section_17 . 2008-10-02 . 1980-01-01 .
  52. Yu AL, Gilman MF, Ozkaynak WB, London S, Kreissman HX, Chen KK, Matthay SL, Cohn JM, Maris JM, Sondel PM . 2009 . A phase III randomized trial of the chimeric anti-GD2 antibody ch14.18 with GM-CSF and IL2 as immunotherapy following dose intensive chemotherapy for high-risk neuroblastoma: Childrens Oncology Group (COG) study ANBL0032 . Journal of Clinical Oncology . 27 . 15 Suppl . 10067z . https://web.archive.org/web/20160110164845/http://meetinglibrary.asco.org/content/35748-65 . 2016-01-10 . 2015-09-10 .
  53. Cermakova . Katerina . Tao . Ling . Dejmek . Milan . Sala . Michal . Montierth . Matthew D. . Chan . Yuen San . Patel . Ivanshi . Chambers . Courtney . Loeza Cabrera . Mario . Hoffman . Dane . Parchem . Ronald J. . Wang . Wenyi . Nencka . Radim . Barbieri . Eveline . Hodges . H. Courtney . 2023-11-23 . Reactivation of the G1 enhancer landscape underlies core circuitry addiction to SWI/SNF . Nucleic Acids Research . 52 . 1 . 4–21 . 10.1093/nar/gkad1081 . 1362-4962 . 37993417. free . 10783513 .
  54. Web site: Drugs Trials Snapshot: Danyelza . U.S. Food and Drug Administration (FDA) . 25 November 2020 . 25 December 2020.
  55. Web site: Drug Approval Package: Danyelza . U.S. Food and Drug Administration (FDA) . 22 December 2020 . 25 December 2020.
  56. Web site: Neuroblastoma overview. Children with Cancer UK. 2020-07-01.
  57. Kushner BH, Kramer K, LaQuaglia MP, Modak S, Yataghene K, Cheung NK . Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma . Journal of Clinical Oncology . 22 . 24 . 4888–4892 . December 2004 . 15611504 . 10.1200/JCO.2004.02.101 .
  58. Kreissman SG, Villablanca JG, Diller L, London WB, Maris JM, Park JR, Reynolds CP, von Allmen D, Cohn SL, Matthay KK . 2007 . Response and toxicity to a dose-intensive multi-agent chemotherapy induction regimen for high risk neuroblastoma (HR-NB): A Children's Oncology Group (COG A3973) study . Journal of Clinical Oncology . 25 . 18 Suppl . 9505 . https://web.archive.org/web/20160110164845/http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/9505 . 2016-01-10 . 10.1200/jco.2007.25.18_suppl.9505.
  59. Ceschel S, Casotto V, Valsecchi MG, Tamaro P, Jankovic M, Hanau G, Fossati F, Pillon M, Rondelli R, Sandri A, Silvestri D, Haupt R, Cuttini M . 6 . Survival after relapse in children with solid tumors: a follow-up study from the Italian off-therapy registry . Pediatric Blood & Cancer . 47 . 5 . 560–566 . October 2006 . 16395684 . 10.1002/pbc.20726 . 31490896 .
  60. Gurney JG, Tersak JM, Ness KK, Landier W, Matthay KK, Schmidt ML . Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: a report from the Children's Oncology Group . Pediatrics . 120 . 5 . e1229–e1236 . November 2007 . 17974716 . 10.1542/peds.2007-0178 . 10606999 .
  61. Trahair TN, Vowels MR, Johnston K, Cohn RJ, Russell SJ, Neville KA, Carroll S, Marshall GM . 6 . Long-term outcomes in children with high-risk neuroblastoma treated with autologous stem cell transplantation . Bone Marrow Transplantation . 40 . 8 . 741–746 . October 2007 . 17724446 . 10.1038/sj.bmt.1705809 . free .
  62. Web site: Mozes A . February 21, 2007 . Childhood Cancer Survivors Face Increased Sarcoma Risk . . live . https://web.archive.org/web/20150908085659/http://consumer.healthday.com/cancer-information-5/bone-cancer-news-92/childhood-cancer-survivors-face-increased-sarcoma-risk-602068.html . September 8, 2015 .
  63. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, Friedman DL, Marina N, Hobbie W, Kadan-Lottick NS, Schwartz CL, Leisenring W, Robison LL . 6 . Chronic health conditions in adult survivors of childhood cancer . The New England Journal of Medicine . 355 . 15 . 1572–1582 . October 2006 . 17035650 . 10.1056/NEJMsa060185 . free .
  64. Laverdière C, Liu Q, Yasui Y, Nathan PC, Gurney JG, Stovall M, Diller LR, Cheung NK, Wolden S, Robison LL, Sklar CA . 6 . Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study . Journal of the National Cancer Institute . 101 . 16 . 1131–1140 . August 2009 . 19648511 . 2728747 . 10.1093/jnci/djp230 .
  65. Janoueix-Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, Lequin D, Vermeulen J, Couturier J, Peuchmaur M, Valent A, Plantaz D, Rubie H, Valteau-Couanet D, Thomas C, Combaret V, Rousseau R, Eggert A, Michon J, Speleman F, Delattre O . 6 . Overall genomic pattern is a predictor of outcome in neuroblastoma . Journal of Clinical Oncology . 27 . 7 . 1026–1033 . March 2009 . 19171713 . 10.1200/JCO.2008.16.0630 . free .
  66. Vandesompele J, Baudis M, De Preter K, Van Roy N, Ambros P, Bown N, Brinkschmidt C, Christiansen H, Combaret V, Lastowska M, Nicholson J, O'Meara A, Plantaz D, Stallings R, Brichard B, Van den Broecke C, De Bie S, De Paepe A, Laureys G, Speleman F . 6 . Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma . Journal of Clinical Oncology . 23 . 10 . 2280–2299 . April 2005 . 15800319 . 10.1200/JCO.2005.06.104 . 2019-11-18 . https://web.archive.org/web/20201030082238/https://www.zora.uzh.ch/id/eprint/18919/2/Vandesompele_Baudis_Neuroblastoma_V.pdf . 2020-10-30 .
  67. Michels E, Vandesompele J, Hoebeeck J, Menten B, De Preter K, Laureys G, Van Roy N, Speleman F . 6 . Genome wide measurement of DNA copy number changes in neuroblastoma: dissecting amplicons and mapping losses, gains and breakpoints . Cytogenetic and Genome Research . 115 . 3–4 . 273–282 . 2006 . 17124410 . 10.1159/000095924 . 14012430 .
  68. Carén H, Erichsen J, Olsson L, Enerbäck C, Sjöberg RM, Abrahamsson J, Kogner P, Martinsson T . 6 . High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene . BMC Genomics . 9 . 353 . July 2008 . 18664255 . 2527340 . 10.1186/1471-2164-9-353 . free .
  69. Book: Brodeur GM, Hogarty MD, Mosse YP, Maris JM . Neuroblastoma . Pizzo PA, Poplack DG . Principles and Practice of Pediatric Oncology . 6th . 1997 . 886–922 . Wolters Kluwer Health/Lippincott Williams & Wilkins . 978-1-60547-682-7.
  70. Franks LM, Bollen A, Seeger RC, Stram DO, Matthay KK . Neuroblastoma in adults and adolescents: an indolent course with poor survival . Cancer . 79 . 10 . 2028–2035 . May 1997 . 9149032 . 10.1002/(SICI)1097-0142(19970515)79:10<2028::AID-CNCR26>3.0.CO;2-V . free .
  71. Howman-Giles R, Shaw PJ, Uren RF, Chung DK . Neuroblastoma and other neuroendocrine tumors . Seminars in Nuclear Medicine . 37 . 4 . 286–302 . July 2007 . 17544628 . 10.1053/j.semnuclmed.2007.02.009 .
  72. Ladenstein R, Pötschger U, Hartman O, Pearson AD, Klingebiel T, Castel V, Yaniv I, Demirer T, Dini G . 6 . 28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures . Bone Marrow Transplantation . 41 . Suppl 2 . S118–S127 . June 2008 . 18545256 . 10.1038/bmt.2008.69 . free .
  73. Book: Berthold F, Simon T . Clinical Presentation . https://books.google.com/books?id=p4f-IkKNSKMC&pg=PA63 . 63–85 . Cheung NK, Cohn SL . 2006 . Neuroblastoma . Springer . 978-3-540-26616-7.
  74. Beckwith JB, Perrin EV . In Situ Neuroblastomas: A Contribution to the Natural History of Neural Crest Tumors . The American Journal of Pathology . 43 . 1089–1104 . December 1963 . 6 . 14099453 . 1949785 .
  75. Rothenberg AB, Berdon WE, D'Angio GJ, Yamashiro DJ, Cowles RA . Neuroblastoma-remembering the three physicians who described it a century ago: James Homer Wright, William Pepper, and Robert Hutchison . Pediatric Radiology . 39 . 2 . 155–160 . February 2009 . 19034443 . 10.1007/s00247-008-1062-z . 19611725 .
  76. Braekeveldt N, Wigerup C, Gisselsson D, Mohlin S, Merselius M, Beckman S, Jonson T, Börjesson A, Backman T, Tadeo I, Berbegall AP, Ora I, Navarro S, Noguera R, Påhlman S, Bexell D . 6 . Neuroblastoma patient-derived orthotopic xenografts retain metastatic patterns and geno- and phenotypes of patient tumours . International Journal of Cancer . 136 . 5 . E252–E261 . March 2015 . 25220031 . 4299502 . 10.1002/ijc.29217 .
  77. Malaney P, Nicosia SV, Davé V . One mouse, one patient paradigm: New avatars of personalized cancer therapy . Cancer Letters . 344 . 1 . 1–12 . March 2014 . 24157811 . 4092874 . 10.1016/j.canlet.2013.10.010 .
  78. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, Arcaroli JJ, Messersmith WA, Eckhardt SG . 6 . Patient-derived tumour xenografts as models for oncology drug development . Nature Reviews. Clinical Oncology . 9 . 6 . 338–350 . April 2012 . 22508028 . 3928688 . 10.1038/nrclinonc.2012.61 .
  79. Web site: Neuroblastoma Committee—Current Focus of Research . 2008-01-13 . https://web.archive.org/web/20060925060348/http://www.curesearch.org/our_research/index_sub.aspx?id=1767 . September 25, 2006 .
  80. Baker DL, Schmidt ML, Cohn SL, Maris JM, London WB, Buxton A, Stram D, Castleberry RP, Shimada H, Sandler A, Shamberger RC, Look AT, Reynolds CP, Seeger RC, Matthay KK . 6 . Outcome after reduced chemotherapy for intermediate-risk neuroblastoma . The New England Journal of Medicine . 363 . 14 . 1313–1323 . September 2010 . 20879880 . 2993160 . 10.1056/NEJMoa1001527 . https://archive.today/20130113023927/http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/9504 . 2013-01-13 .
  81. Baker DL, Schmidt ML, Cohn SL, Maris JM, London WB, Buxton A, Stram D, Castleberry RP, Shimada H, Sandler A, Shamberger RC, Look AT, Reynolds CP, Seeger RC, Matthay KK . 6 . Outcome after reduced chemotherapy for intermediate-risk neuroblastoma . The New England Journal of Medicine . 363 . 14 . 1313–1323 . September 2010 . 20879880 . 2993160 . 10.1056/NEJMoa1001527 .
  82. Morgenstern DA, Baruchel S, Irwin MS . Current and future strategies for relapsed neuroblastoma: challenges on the road to precision therapy . Journal of Pediatric Hematology/Oncology . 35 . 5 . 337–347 . July 2013 . 23703550 . 10.1097/MPH.0b013e318299d637 . 5529288 .
  83. Illhardt T, Toporski J, Feuchtinger T, Turkiewicz D, Teltschik HM, Ebinger M, Schwarze CP, Holzer U, Lode HN, Albert MH, Gruhn B, Urban C, Dykes JH, Teuffel O, Schumm M, Handgretinger R, Lang P . 6 . Haploidentical Stem Cell Transplantation for Refractory/Relapsed Neuroblastoma . Biology of Blood and Marrow Transplantation . 24 . 5 . 1005–1012 . May 2018 . 29307718 . 10.1016/j.bbmt.2017.12.805 . Elsevier BV . free .
  84. Georgantzi . Kleopatra . Tsolakis . Apostolos V. . Stridsberg . Mats . Jakobson . Åke . Christofferson . Rolf . Janson . Eva Tiensuu . April 2011 . Differentiated expression of somatostatin receptor subtypes in experimental models and clinical neuroblastoma: Expression of Somatostatin Receptors in Neuroblastoma . Pediatric Blood & Cancer . en . 56 . 4 . 584–589 . 10.1002/pbc.22913. 21298743 . 33330859 .
  85. Gains . Jennifer E. . Sebire . Neil J. . Moroz . Veronica . Wheatley . Keith . Gaze . Mark N. . 2018-03-01 . Immunohistochemical evaluation of molecular radiotherapy target expression in neuroblastoma tissue . European Journal of Nuclear Medicine and Molecular Imaging . en . 45 . 3 . 402–411 . 10.1007/s00259-017-3856-4 . 29043399 . 30833979 . 1619-7089.
  86. Albers . Anne R . O'Dorisio . M. Sue . Balster . Douglas A . Caprara . Moonkyung . Gosh . Pradip . Chen . Feng . Hoeger . Carl . Rivier . Jean . Wenger . Gail D . O'Dorisio . Thomas M . Qualman . Stephen J . 2000-03-17 . Somatostatin receptor gene expression in neuroblastoma . Regulatory Peptides . en . 88 . 1 . 61–73 . 10.1016/S0167-0115(99)00121-4 . 10706954 . 11168638 . 0167-0115.
  87. Gains JE, Bomanji JB, Fersht NL, Sullivan T, D'Souza D, Sullivan KP, Aldridge M, Waddington W, Gaze MN . 6 . 177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma . Journal of Nuclear Medicine . 52 . 7 . 1041–1047 . July 2011 . 21680680 . 10.2967/jnumed.110.085100 . 38660848 . free .
  88. Kong G, Hofman MS, Murray WK, Wilson S, Wood P, Downie P, Super L, Hogg A, Eu P, Hicks RJ . 6 . Initial Experience With Gallium-68 DOTA-Octreotate PET/CT and Peptide Receptor Radionuclide Therapy for Pediatric Patients With Refractory Metastatic Neuroblastoma . Journal of Pediatric Hematology/Oncology . 38 . 2 . 87–96 . March 2016 . 26296147 . 10.1097/MPH.0000000000000411 . 25518501 .
  89. Menda Y, O'Dorisio MS, Kao S, Khanna G, Michael S, Connolly M, Babich J, O'Dorisio T, Bushnell D, Madsen M . 6 . Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors . Journal of Nuclear Medicine . 51 . 10 . 1524–1531 . October 2010 . 20847174 . 3753801 . 10.2967/jnumed.110.075226 .
  90. https://inrgdb.org/ INRG Data Commons
  91. https://commons.cri.uchicago.edu/ Pediatric Cancer Data Commons
  92. Web site: Home. Advances in Neuroblastoma Research Association . 26 April 2014 . 11 April 2024.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Neuroblastoma".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.